In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Albireo Pharma Inc. (NASDAQ:ALBO) reported that Perceptive Advisors has picked up 845,000 of common stock as of 2017-06-05.
The acquisition brings the aggregate amount owned by Perceptive Advisors to a total of 845,000 representing less than 9.94% stake in the company.
For those not familiar with the company, Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to address unmet needs in orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a third product candidate for which an application for regulatory approval has been submitted in Japan. Albireo’s lead product candidate, A4250, is nearing initiation of Phase 3 clinical development in patients with progressive familial intrahepatic cholestasis (PFIC).
A glance at Albireo Pharma Inc. (NASDAQ:ALBO)’s key stats reveals a current market capitalization of 173.00 Million based on 8.49 Million shares outstanding and a price at last close of $19.92 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2013-12-20, Lieberman picked up 10,800 at a purchase price of $2.29. This brings their total holding to 11,292 as of the date of the filing.
On the sell side, the most recent transaction saw Pereira unload 4,734 shares at a sale price of $2.26. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Albireo Pharma Inc. (NASDAQ:ALBO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.